Phase II Trail of REVLIMID (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas

Grants and Contracts Details

StatusFinished
Effective start/end date2/2/06 → 6/24/20

Funding

  • Celgene: $194,625.00